OptimizeRx Corp. (NASDAQ:OPRX) Receives $13.43 Consensus Target Price from Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has earned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.4286.

A number of equities research analysts have recently commented on OPRX shares. UBS Group set a $10.00 price target on shares of OptimizeRx in a report on Wednesday, May 13th. Weiss Ratings lowered shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. Wall Street Zen cut shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Roth Mkm decreased their price objective on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Lake Street Capital lowered their price objective on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th.

OptimizeRx Price Performance

OPRX opened at $4.94 on Monday. The firm has a market cap of $92.67 million, a P/E ratio of 14.11 and a beta of 1.19. The business’s fifty day simple moving average is $6.25 and its 200 day simple moving average is $10.13. OptimizeRx has a 52 week low of $4.57 and a 52 week high of $22.25. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. As a group, equities research analysts anticipate that OptimizeRx will post 0.5 EPS for the current fiscal year.

OptimizeRx announced that its Board of Directors has initiated a share repurchase program on Thursday, March 5th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Institutional Trading of OptimizeRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Segall Bryant & Hamill LLC purchased a new position in shares of OptimizeRx during the 1st quarter worth about $1,185,000. Quantinno Capital Management LP grew its holdings in OptimizeRx by 180.1% in the first quarter. Quantinno Capital Management LP now owns 49,022 shares of the company’s stock valued at $308,000 after purchasing an additional 31,518 shares during the period. Rice Hall James & Associates LLC raised its stake in OptimizeRx by 1.9% during the first quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after purchasing an additional 11,247 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of OptimizeRx by 633.2% in the 1st quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock valued at $1,362,000 after purchasing an additional 187,278 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of OptimizeRx by 83.4% in the 1st quarter. Sei Investments Co. now owns 98,633 shares of the company’s stock valued at $619,000 after purchasing an additional 44,844 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.